Participant flow

Concordance of Key Actionable Genomic Alterations as Assessed in Tumor Tissue and Plasma in Non Small Cell Lung Cancer · Source last updated 2020-11-17

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Patients with non-squamous NSCLC regardless of genomic alteration status (newly diagnosed or progressing on therapy)

   id

   FG000

   title

   A - NSCLC All Comers Regardless of Genomic Alteration Status

2. description

   Patients with non-squamous NSCLC progressing on erlotinib, gefitinib, or afatinib

   id

   FG001

   title

   B - Progressing on EGFR Targeted Therapies

periods

1. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         121

      2. group Id

         FG001

         num Subjects

         19

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         121

      2. group Id

         FG001

         num Subjects

         19

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         0

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice